Company Overview of Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal, and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in...
1801 Century Park East
Los Angeles, CA 90067
Founded in 2004
Key Executives for Ritter Pharmaceuticals, Inc.
Chief Executive Officer and Director
Founder, President and Director
Executive Chairman and Chief Strategic Officer
Senior Clinical & Regulatory Advisor
Compensation as of Fiscal Year 2014.
Ritter Pharmaceuticals, Inc. Key Developments
Ritter Pharmaceuticals, Inc. Appoints Gerald T. Proehl to its Board of Directors
Apr 22 15
Ritter Pharmaceuticals, Inc. announced that Gerald T. Proehl has joined the Company’s Board of Directors. With his appointment, the Ritter Pharma Board now has seven Directors. Mr. Proehl will chair the Company’s nominating and corporate governance committee. Mr. Proehl served as President, Chief Executive Officer and Director of Santarus, Inc. from 2002 through the company’s acquisition in January 2014 by Salix Pharmaceuticals, Inc. for $2.6 billion.
Ritter Pharmaceuticals, Inc. Appoints Paul V. Maier as a Board of Directors
Apr 14 15
Ritter Pharmaceuticals, Inc. appointed Paul V. Maier as a Board of Directors. Mr. Maier will chair the company’s audit committee. Mr. Maier served for five years as the Chief Financial Officer of life sciences company Sequenom, Inc. He previously served for 15 years as the Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. Mr. Maier currently serves on the Boards of Directors of International Stem Cell Corporation, Apricus Biosciences, MabVax Therapeutics and Biological Dynamics.
Ritter Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Mar 23 15
Ritter Pharmaceuticals, Inc. filed its S-1 on Mar 23, 2015 for the period ending Dec 31, 2014. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 4, 2014